Renee, AML and Breast Cancer SurvivorWith Her Daughter

An Expression Makes a World of Difference

By creating medicines to control gene expression, we aim to make a profound difference in the lives of patients and their families.

Our Message to Patients
Nancy Simonian, M.D.Chief Executive Officer

Our Message to Patients

At the heart of all our efforts at Syros is our dedication to advancing medicines that provide a profound benefit for patients with difficult-to-treat diseases.

Read Our Message

Diseases We Target

We have a singular focus on developing and delivering new standards of care for the frontline treatment of hematologic malignancies. We currently have programs in clinical development for genomically defined patients with MDS, AML and APL. We are exploring out-licensing opportunities for our SY-5609 clinical program, an oral reversible CDK7 with best-in-class selectivity and potency, enabling broad development potential. We are also exploring out-licensing opportunities for our preclinical oncology programs, consisting of potential first-in-class and best-in-class assets.  

Read More About the Diseases We Target
Our Clinical Trials
RobertMDS Patient

Our Clinical Trials

Interested in participating in a clinical trial?

Learn More About Our Clinical Trials